265 related articles for article (PubMed ID: 17686055)
21. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
22. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
Amatori S; Bagaloni I; Viti D; Fanelli M
Lung Cancer; 2011 Jan; 71(1):113-5. PubMed ID: 21095037
[TBL] [Abstract][Full Text] [Related]
23. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
24. Decitabine for acute myeloid leukemia.
Marks PW
Expert Rev Anticancer Ther; 2012 Mar; 12(3):299-305. PubMed ID: 22369322
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation.
Fabianowska-Majewska K; Wyczechowska D; Czyz M
Adv Exp Med Biol; 2000; 486():343-7. PubMed ID: 11783512
[No Abstract] [Full Text] [Related]
26. Decitabine--bedside to bench.
Oki Y; Aoki E; Issa JP
Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
[TBL] [Abstract][Full Text] [Related]
27. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Appleton K; Mackay HJ; Judson I; Plumb JA; McCormick C; Strathdee G; Lee C; Barrett S; Reade S; Jadayel D; Tang A; Bellenger K; Mackay L; Setanoians A; Schätzlein A; Twelves C; Kaye SB; Brown R
J Clin Oncol; 2007 Oct; 25(29):4603-9. PubMed ID: 17925555
[TBL] [Abstract][Full Text] [Related]
29. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L; Flynn J; Plass C; Marcucci G; Chan KK; Grever MR; Byrd JC
Br J Haematol; 2010 Jul; 150(2):189-95. PubMed ID: 20456354
[TBL] [Abstract][Full Text] [Related]
31. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
32. 5-azacytidine reverses drug resistance in bladder cancer cells.
Ramachandran K; Gordian E; Singal R
Anticancer Res; 2011 Nov; 31(11):3757-66. PubMed ID: 22110197
[TBL] [Abstract][Full Text] [Related]
33. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
Aparicio A; North B; Barske L; Wang X; Bollati V; Weisenberger D; Yoo C; Tannir N; Horne E; Groshen S; Jones P; Yang A; Issa JP
Epigenetics; 2009 Apr; 4(3):176-84. PubMed ID: 19421002
[TBL] [Abstract][Full Text] [Related]
34. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
35. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
36. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Segura-Pacheco B; Trejo-Becerril C; Perez-Cardenas E; Taja-Chayeb L; Mariscal I; Chavez A; Acuña C; Salazar AM; Lizano M; Dueñas-Gonzalez A
Clin Cancer Res; 2003 May; 9(5):1596-603. PubMed ID: 12738711
[TBL] [Abstract][Full Text] [Related]
38. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Amatori S; Papalini F; Lazzarini R; Donati B; Bagaloni I; Rippo MR; Procopio A; Pelicci PG; Catalano A; Fanelli M
Lung Cancer; 2009 Nov; 66(2):184-90. PubMed ID: 19233506
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy.
Nyce JW
Mutat Res; 1997 Apr; 386(2):153-61. PubMed ID: 9113116
[No Abstract] [Full Text] [Related]
40. Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines.
Onda K; Suzuki R; Tanaka S; Oga H; Oka K; Hirano T
Anticancer Res; 2012 Oct; 32(10):4439-44. PubMed ID: 23060570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
